Skip to content

Autoimmune Diabetes: Markers of the Disease and Treatment of Latent Autoimmune Diabetes in Adults (LADA)

Autoimmune Diabetes: Disease Markers and Treatment of Latent Autoimmune Diabetes in Adults (LADA)

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01148238
Enrollment
0
Registered
2010-06-22
Start date
2012-08-31
Completion date
2012-12-31
Last updated
2012-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Diabetes

Keywords

Autoimmune diabetes, LADA, T-reg, cytokine

Brief summary

Autoimmunity is the main cause of diabetes type 1 and an important factor as cause of Latent Autoimmune Diabetes in Adults (LADA). Recently, research has found that being deficient of T-reg cells is an important cause of autoimmunity. The study hypothesis are: 1. Patients with newly found diabetes type 1 have less T-reg than healthy. 2. Patients with newly found diabetes type 1 have less T-reg than patients with long duration of the illness. 3. The number of T-reg is negative associated with HLA-risk-haplotype. 4. The number of T-reg is negative associated with LADA. 5. Differences relating to inflammatory cytokines will be seen among patients with newly found diabetes type 1, but not among others.

Detailed description

Research has worked out that b-cells are being destroyed by cytokines released from inflammatory cells. One hypothesis in that T-reg is a cause of autoimmunity, and that T-reg concentrations are low in patients with newly diagnosed diabetes type 1. Blood samples will be taken from 10 patients with newly diagnosed type 1 diabetes, Latent Autoimmune Diabetes in Adults (LADA) and type 1 diabetes older than 10 years and the same amount of samples from healthy, age- and sex-matched blood donors. Markers of autoimmune diabetes will be analyzed.

Interventions

None listed

Sponsors

Norwegian University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* newly diagnosed diabetes type 1 * LADA * diabetes type 1 older than 10 years

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frame
T-reg

Secondary

MeasureTime frame
HLA, anti-GAD, anti-IA2, white blood count, CRP, fasting C-peptide, HbA1c

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026